Source : Nasdaq
As the ongoing COVID-19 outbreak continues to worsen, the U.S. Food and Drug Administration (FDA) announced that it will postpone all foreign inspections, effective immediately.
The agency said it won’t conduct inspections of foreign manufacturing facilities until the end of April. However, inspections outside the country that are designated “mission-critical” will still be considered on a case-by-case basis.
“We are aware of how this action may impact other FDA responsibilities, including product application reviews,” the agency said in a statement. “We will be vigilant and monitor the situation very closely and will try to mitigate potential impacts from this outbreak in lockstep with the whole of the federal government.”
Although the FDA promises to resume inspections as soon as possible, there’s a strong possibility that it could extend this inspection halt well past April if the outbreak gets worse.